Exclusive Summary

• As a gold-standard first-line chronic medication on the WHO Essential Medicines List, it serves a massive global pool of over 50 million epilepsy patients, ensuring immense and highly stable long-term recurring orders for distributors.
• The 100mg dosage perfectly aligns with the clinical necessity for 'start low, go slow' initial dose titration and pediatric administration, offering a differentiated promotional angle in a market saturated with standard 200mg generics.
• Operating in a fully mature off-patent market, our vertically integrated Chinese supply chain guarantees a risk-free stable supply and tremendous price competitiveness against the originator and other global generics.
• Fully backed by a robust quality framework and comprehensive registration dossiers (CTD format and BE data), enabling global distributors to achieve rapid localized market authorization and win public hospital tenders.